These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 33749319)
1. Influence of RFC1 c.80A>G Polymorphism on Methotrexate-Mediated Toxicity and Therapeutic Efficacy in Rheumatoid Arthritis: A Meta-analysis. Naushad SM; Alrokayan SA; Almajhdi FN; Hussain T Ann Pharmacother; 2021 Dec; 55(12):1429-1438. PubMed ID: 33749319 [TBL] [Abstract][Full Text] [Related]
2. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis. Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001 [TBL] [Abstract][Full Text] [Related]
3. RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies. Kung TN; Dennis J; Ma Y; Xie G; Bykerk V; Pope J; Thorne C; Keystone E; Siminovitch KA; Gagnon F Arthritis Rheumatol; 2014 May; 66(5):1111-20. PubMed ID: 24782176 [TBL] [Abstract][Full Text] [Related]
4. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Samara SA; Irshaid YM; Mustafa KN Int J Clin Pharmacol Ther; 2014 Sep; 52(9):746-55. PubMed ID: 25074866 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. Plaza-Plaza JC; Aguilera M; Cañadas-Garre M; Chemello C; González-Utrilla A; Faus Dader MJ; Calleja MA OMICS; 2012 Nov; 16(11):589-95. PubMed ID: 23095111 [TBL] [Abstract][Full Text] [Related]
6. The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Nomair AM; Abdelati A; Dwedar FI; Elnemr R; Kamel YN; Nomeir HM Clin Rheumatol; 2024 Mar; 43(3):971-983. PubMed ID: 38311638 [TBL] [Abstract][Full Text] [Related]
7. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736 [TBL] [Abstract][Full Text] [Related]
8. Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis. Tazoe Y; Hayashi H; Tsuboi S; Shioura T; Matsuyama T; Yamada H; Hirai K; Tsuji D; Inoue K; Sugiyama T; Itoh K Drug Metab Pharmacokinet; 2015 Jun; 30(3):227-30. PubMed ID: 26003891 [TBL] [Abstract][Full Text] [Related]
10. Association of Wang S; Zuo S; Liu Z; Ji X; Yao Z; Wang X J Int Med Res; 2020 Feb; 48(2):300060519879588. PubMed ID: 31617429 [TBL] [Abstract][Full Text] [Related]
11. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Lee YH; Bae SC Rheumatol Int; 2016 Nov; 36(11):1591-1599. PubMed ID: 27379764 [TBL] [Abstract][Full Text] [Related]
12. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Hayashi H; Tazoe Y; Tsuboi S; Horino M; Morishita M; Arai T; Ohshima M; Matsuyama T; Kosuge K; Yamada H; Tsuji D; Inoue K; Itoh K Drug Metab Pharmacokinet; 2013; 28(2):164-8. PubMed ID: 22971639 [TBL] [Abstract][Full Text] [Related]
13. Lack of association between MTHFR A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta-analysis. Fan H; Li Y; Zhang L; Li Y; Li W Int J Rheum Dis; 2017 May; 20(5):526-540. PubMed ID: 28544525 [TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of the association between the ATIC 347 C/G polymorphism and methotrexate responsiveness and toxicity in rheumatoid arthritis. Lee YH; Song GG Semin Arthritis Rheum; 2024 Feb; 64():152337. PubMed ID: 38071832 [TBL] [Abstract][Full Text] [Related]
15. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis. He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986 [TBL] [Abstract][Full Text] [Related]
16. Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis. Świerkot J; Ślęzak R; Karpiński P; Pawłowska J; Noga L; Szechiński J; Wiland P Pol Arch Med Wewn; 2015; 125(3):152-61. PubMed ID: 25599563 [TBL] [Abstract][Full Text] [Related]
17. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Ghodke-Puranik Y; Puranik AS; Shintre P; Joshi K; Patwardhan B; Lamba J; Niewold TB; Chopra A Pharmacogenomics; 2015 Dec; 16(18):2019-34. PubMed ID: 26616421 [TBL] [Abstract][Full Text] [Related]
18. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Cáliz R; del Amo J; Balsa A; Blanco F; Silva L; Sanmarti R; Martínez FG; Collado MD; Ramirez Mdel C; Tejedor D; Artieda M; Pascual-Salcedo D; Oreiro N; Andreu JL; Graell E; Simon L; Martínez A; Mulero J Scand J Rheumatol; 2012 Feb; 41(1):10-4. PubMed ID: 22044028 [TBL] [Abstract][Full Text] [Related]
19. Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis. Muralidharan N; Mariaselvam CM; Mithun CB; Negi VS Clin Rheumatol; 2016 Apr; 35(4):879-85. PubMed ID: 25771854 [TBL] [Abstract][Full Text] [Related]
20. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. van Ede AE; Laan RF; Blom HJ; Boers GH; Haagsma CJ; Thomas CM; De Boo TM; van de Putte LB Rheumatology (Oxford); 2002 Jun; 41(6):658-65. PubMed ID: 12048292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]